Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000190757 | SCV000244198 | uncertain significance | Inborn genetic diseases | 2014-10-24 | criteria provided, single submitter | clinical testing | The c.3383T>C (p.L1128P) alteration is located in exon 32 (coding exon 32) of the PHKA2 gene. This alteration results from a T to C substitution at nucleotide position 3383, causing the leucine (L) at amino acid position 1128 to be replaced by a proline (P). The alteration is not observed in healthy cohorts:_x000D_ Based on data from the NHLBI Exome Sequencing Project (ESP), the PHKA2 c.3383T>C alteration was not observed among 6,503 individuals tested. Allele frequency data for this nucleotide position are not currently available from the 1000 Genomes Project and the alteration is not currently listed in the Database of Single Nucleotide Polymorphisms (dbSNP)._x000D_ Though some variants may appear to be rare due to database-specific ethnic underrepresentation, rare missense alleles commonly exhibit a deleterious effect on protein function (Kryukov, 2007; Tennessen, 2012). IF USED, PULL THESE INTO REFERENCES:_x000D_ Kryukov GV, et al. (2007) Am J Hum Genet 80:727-739. Tennessen JA, et al. (2012) Science 337(64):64-69. The altered amino acid is conserved throughout evolution:_x000D_ The p.L1128 amino acid is completely conserved in available vertebrate species. The amino acid is located in a functionally important protein domain:_x000D_ The p.L1128P amino acid is located within the CBL-like domain D of the PhK aL protein. This domain is predicted to interact with the regulatory domain of the catalytic PhK g subunit of the phosphorylase kinase (PhK) complex (Carriere, 2008). Missense mutations within this domain probably lead to an unstable or less regulated PhK holoenzyme and typically result in an XLG-I phenotype (Carriere, 2008). The alteration is predicted deleterious by in silico models:_x000D_ The p.L1128P alteration is predicted to be probably damaging by Polyphen and deleterious by SIFT in silico analyses. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Mendelics | RCV000990491 | SCV001141493 | likely pathogenic | Glycogen storage disease IXa1 | 2019-05-28 | criteria provided, single submitter | clinical testing |